Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has reported promising clinical data on their immunotherapies, eftilagimod alpha (efti) and IMP761, for treating various cancers and autoimmune diseases. Notably, a Phase II trial for metastatic breast cancer showed a high safety profile and a 50% overall response rate for efti, while an ongoing Phase IIb trial in head and neck cancer revealed a 26.9% response rate in PD-L1 negative patients. Preparations for a Phase III lung cancer trial and the progression of IMP761 towards human trials are underway, with further updates expected in the current year.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
